Investor Calendar Invites You to the Chembio Second Quarter 2016 Earnings Conference Call and Webcast Live on Thursday, August 11, 2016
MEDFORD, NY / ACCESSWIRE / August 10, 2016 / Chembio Diagnostics, Inc. (CEMI) will host a conference call and live webcast to discuss the results of the second quarter 2016, to be held Thursday, August 11, 2016 at 10:00 AM Eastern Time.
To participate in this event, dial 877-407-0778 domestically, or 201-689-8565 internationally, approximately 5 to 10 minutes before the beginning of the call. Additionally, you can listen to the event online at www.investorcalendar.com/IC/CEPage.asp?ID=175233 as well as via the Chembio Diagnostics, Inc. website (www.chembio.com).
If you are unable to participate during the live webcast, the event archive will be available at www.investorcalendar.com or www.chembio.com.
You may access the teleconference replay by dialing 877-481-4010 domestically or 919-882-2331 internationally, referencing conference ID # 13642880. The replay will be available beginning approximately 2 hours after the completion of the live event, ending at midnight Eastern on August 18, 2016.
About Chembio Diagnostics
Chembio Diagnostics, Inc. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $8.0 billion point-of-care testing market. Chembio markets its DPP® HIV 1/2 Assay, HIV 1/2 STAT-PAK® Assay and SURE CHECK® HIV 1/2 Assay, with these Chembio brand names, in the U.S. and internationally both directly and through third-party distributors. SURE CHECK® HIV 1/2 Assay previously has been sold in the U.S. exclusively as Clearview® Complete HIV 1/2 Assay. Outside the U.S., Chembio markets its SURE CHECK® HIV 1/2 Assays through distributors.
Chembio has developed a patented point-of-care test platform technology, the Dual Path Platform (DPP®) technology, which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products.
Headquartered in Medford, NY, Chembio is licensed by the U.S. Food and Drug Administration (FDA) as well as the U.S. Department of Agriculture (USDA), and is certified for the global market under the International Standards Organization (ISO) directive 13485. Chembio Diagnostic Systems, Inc. is a wholly-owned subsidiary of Chembio Diagnostics, Inc. For more information, please visit: www.chembio.com.
SOURCE: Investor Calendar
